Experts Urge Family Members and Friends to Seek Immediate Intervention for Their Loved Ones Who May Have Alzheimer's Di...(Gail Hunt president and CEO National All...),Health

About Alzheimer's Disease

Alzheimer's disease is the most common type of dementia, affecting more than five million Americans. Symptoms of AD may include increased forgetfulness, repeating or asking the same question frequently, and problems making decisions. These symptoms gradually affect a person's cognition, behavior and everyday activities, some severe enough to have an impact on their work, social activities and family life. While there is no cure for AD, there are treatments to help slow the progression of the symptoms of the disease. The disease disproportionately affects Hispanics and African Americans as they are at higher risk than Caucasians for developing the disease, and often go undiagnosed and untreated for longer periods of time.

About Eisai Inc.

Eisai Inc. is a U.S. pharmaceutical subsidiary of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: neurology, gastrointestinal disorders and oncology/critical care. Established in 1995 and ranked among the top-20 U.S. pharmaceutical companies (based on retail sales), Eisai Inc. began marketing its first product in the United States in 1997 and has rapidly grown to become an integrated pharmaceutical business with fiscal year 2007 (year ended March 31, 2008) sales of approximately $3 billion, including the results of the acquisition of MGI PHARMA, Inc.

Eisai Inc. employs approximately 1,900 people at its headquarters in Woodcliff Lake, NJ, at its state-of-the-art pharmaceutical production and formulation research and development facility in Research Triangle Park, NC, and in the field. For more information about
'/>"/>